Latest News-RemeGen Co., Ltd Mediaroom_Page

RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China

YANTAI, China, Oct. 29, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK...

2024-10-29 12:00 1358

First patient enrollment in the U.S. - A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis

YANTAI, China, Aug. 6, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" o...

2024-08-06 17:00 2040

RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment

YANTAI, China, June 5, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" ...

2024-06-05 21:42 2436

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88

YANTAI, China, June 4, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" ...

2024-06-04 09:38 1574

RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome

YANTAI, China, May 21, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" o...

2024-05-21 17:35 1754

RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing

The biotech company continues to offer hope to systemic lupus erythematosus ( SLE) patients globally...

2024-05-10 16:26 2364

RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome

YANTAI, China, April 3, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" ...

2024-04-03 11:14 1984

RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024

YANTAI, China, March 11, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" ...

2024-03-11 10:36 1821

World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap

YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or...

2024-02-02 21:30 2346

RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

YANTAI, China, Jan. 12, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK...

2024-01-12 18:17 2025

RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment

YANTAI, China, Dec. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" ...

2023-12-28 15:45 2253

RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients

YANTAI, China, Dec. 18, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" ...

2023-12-18 20:56 1602

RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO)

YANTAI, China, Nov. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" ...

2023-11-28 09:48 2127

RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology

YANTAI, China, Nov. 15, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen"...

2023-11-15 16:35 1833

Remegen's Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis

YANTAI, China, Sept. 27, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen...

2023-09-27 09:30 3346

RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal

YANTAI, China, July 25, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen"...

2023-07-25 16:00 1748

RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

The partnership focuses on combining novel antibody-drug conjugates RC88 and RC108 with a PD-1 inhi...

2023-07-10 10:24 2335

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" ...

2023-06-05 21:26 2902

RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name

The "B" marker is removed from the Company's stock short name YANTAI, China, June 5, 2023 /PRNewswi...

2023-06-05 21:17 3680

RemeGen Celebrates World Intellectual Property Day 2023

YANTAI, China, April 26, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen...

2023-04-26 10:00 2657